Recent Updates
Recently added Catalysts
QTRX Positive Sentiment

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

Wednesday, October 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Quanterix Corporation and Innovita Biological Technology have received regulatory approvals from China's National Medical Products Administration. This partnership aims to enhance access to Quanterix's SIMOA technology and neurology biomarker testing in the Chinese market. The collaboration is expected to significantly improve diagnostic capabilities in the region.

Market Sentiment Analysis

POSITIVE FACTORS

  • Regulatory approvals enhance access to advanced diagnostics in China.
  • Collaboration with Innovita expands market reach for Quanterix's technology.
  • Quanterix's SIMOA technology offers ultra-sensitive biomarker testing.

Full Press Release Details

BILLERICA, Mass. & BEIJING--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market. Initially formed in 2024, the commercialization arrangement combines Quanterix’s ultra-sensitive biomarker de

Frequently Asked Questions

What technology is being expanded in China?

Quanterix's SIMOA technology for neurology biomarker testing is being expanded.

Who are the partners in this collaboration?

The collaboration is between Quanterix Corporation and Innovita Biological Technology.

What approvals did Quanterix and Innovita receive?

They received regulatory approvals from China's National Medical Products Administration.

When was the commercialization arrangement formed?

The commercialization arrangement was initially formed in 2024.

ShareAdd on Google
Tags: QTRX Quanterix Innovita IVD China biomarker testing
Last updated: Oct 7, 2026

Biotech snapshot

Cash runway
$94M liquidity · $2M/mo burn
~53 mo
Minimal dilution risk